scholarly journals Screening for candidate genes related to breast cancer with cDNA microarray analysis

2015 ◽  
Vol 1 (2) ◽  
pp. 65-72 ◽  
Author(s):  
Yu-Juan Xiang ◽  
Qin-Ye Fu ◽  
Zhong-Bing Ma ◽  
De-Zong Gao ◽  
Qiang Zhang ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Candidate Genes ◽  
Microarray Analysis ◽  
Cdna Microarray ◽  
Cdna Microarray Analysis

scholarly journals Transcriptomic identification of candidate genes involved in sunflower responses to chilling and salt stresses based on cDNA microarray analysis

2008 ◽  
Vol 8 (1) ◽  
pp. 11 ◽  
Author(s):  
Paula Fernandez ◽  
Julio Di Rienzo ◽  
Luis Fernandez ◽  
H Esteban Hopp ◽  
Norma Paniego ◽  
...  
Keyword(s):  
Candidate Genes ◽  
Microarray Analysis ◽  
Cdna Microarray ◽  
Cdna Microarray Analysis

Distinct Molecular Signature of Inflammatory Breast Cancer by cDNA Microarray Analysis

2005 ◽  
Vol 93 (3) ◽  
pp. 237-246 ◽  
Author(s):  
Steven Van Laere ◽  
Ilse Van der Auwera ◽  
Gert G. Van den Eynden ◽  
Stephen B. Fox ◽  
Fabrizio Bianchi ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Microarray Analysis ◽  
Cdna Microarray ◽  
Inflammatory Breast Cancer ◽  
Molecular Signature ◽  
Cdna Microarray Analysis

Investigation of aberrant DNA methylation in association with cisplatin-resistant hepatoblastoma.

2019 ◽  
Vol 37 (4_suppl) ◽  
pp. 258-258
Author(s):  
Sunao Fujiyoshi ◽  
Shohei Honda ◽  
Eiso Hiyama ◽  
Akinobu Taketomi
Keyword(s):  
Candidate Genes ◽  
Microarray Analysis ◽  
Cdna Microarray ◽  
Methylation Status ◽  
Cdna Microarray Analysis ◽  
Array Analysis ◽  
Methylation Array ◽  
A Genome ◽  
Differentially Methylated Genes ◽  
Resistant Cells

258 Background: Cisplatin (CDDP) is a key-drug of mainstream treatment for hepatoblastoma (HB), but 22.3% of HB patients have resistance to CDDP, and their prognoses are poor. We investigated methylation status of HB patients and identified CDDP resistant candidate genes in HB. Methods: First, we performed a genome-wide methylation array analysis of 11 resected HB tumors. These cases included six cases of RECIST (Response Evaluation Criteria In Solid Tumors) CR or PR (S group) and five cases of SD or PD (R group). We analyzed methylation status of these patients, comparing with clinical course, and selected significant differentially methylated genes. Next, We made CDDP-resistant HepG2 cells by repeated CDDP treatments for a year, then compared expression levels between the CDDP-resistant cells and original cells, using cDNA microarray analysis. We selected CDDP resistant candidate genes from these data. Results: In methylation array analysis data, unsupervised hierarchical clustering analysis showed that methylation profiles were separable into 2 groups in accord with clinical S group and R group. In principal component analysis, the S group also showed a different methylation pattern to the R group. We compared survival rates using Kaplan-Meier method, and results showed that the R group had poorer prognosis significantly. The R group showed 336 hypermethylated genes and 106 hypomethylated genes around the transcriptional start site compared with S group significantly. And in cDNA microarray analysis, 1271 genes were downregulated and 1571 genes were upregulated significantly in CDDP-resistant cells. From among these genes, we selected 15 suppressor and 8 promoter candidate genes that could be related to CDDP-resistance. Conclusions: We identified methylation status associated with CDDP resistance and poor prognosis, and 23 candidates genes in HB. Further refining might lead us to find out the pathogenesis of chemoresistance or new target of therapies and biomarkers in HB.

Sign in / Sign up

Export Citation Format

Share Document